Clinuvel Pharmaceuticals Ltd
ASX:CUV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.79
17.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd
Cash from Financing Activities
Clinuvel Pharmaceuticals Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Financing Activities
-AU$3.6m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Cash from Financing Activities
AU$76m
|
CAGR 3-Years
13%
|
CAGR 5-Years
57%
|
CAGR 10-Years
28%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Financing Activities
$40.3m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Financing Activities
-$1.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-1%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Financing Activities
AU$10.2m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Financing Activities
AU$90.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
60%
|
CAGR 10-Years
32%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Cash from Financing Activities?
Cash from Financing Activities
-3.6m
AUD
Based on the financial report for Jun 30, 2024, Clinuvel Pharmaceuticals Ltd's Cash from Financing Activities amounts to -3.6m AUD.
What is Clinuvel Pharmaceuticals Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-28%
Over the last year, the Cash from Financing Activities growth was -59%. The average annual Cash from Financing Activities growth rates for Clinuvel Pharmaceuticals Ltd have been -34% over the past three years , -28% over the past five years .
You don't have any saved screeners yet
